HK1254030A1 - 治疗自身免疫病症和同种免疫病症的方法 - Google Patents

治疗自身免疫病症和同种免疫病症的方法 Download PDF

Info

Publication number
HK1254030A1
HK1254030A1 HK18112887.1A HK18112887A HK1254030A1 HK 1254030 A1 HK1254030 A1 HK 1254030A1 HK 18112887 A HK18112887 A HK 18112887A HK 1254030 A1 HK1254030 A1 HK 1254030A1
Authority
HK
Hong Kong
Prior art keywords
methods
individual
treating autoimmune
alloimmune
present disclosure
Prior art date
Application number
HK18112887.1A
Other languages
English (en)
Chinese (zh)
Inventor
格雷汉姆‧帕里
格雷漢姆‧帕里
帕维尔‧A‧尼基廷
桑迪普‧帕尼克
帕維爾‧A‧尼基廷
Original Assignee
比奥贝拉蒂美国公司
比奧貝拉蒂美國公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比奥贝拉蒂美国公司, 比奧貝拉蒂美國公司 filed Critical 比奥贝拉蒂美国公司
Publication of HK1254030A1 publication Critical patent/HK1254030A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18112887.1A 2015-06-26 2016-06-23 治疗自身免疫病症和同种免疫病症的方法 HK1254030A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185362P 2015-06-26 2015-06-26
US62/185,362 2015-06-26

Publications (1)

Publication Number Publication Date
HK1254030A1 true HK1254030A1 (zh) 2019-07-12

Family

ID=57585852

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112887.1A HK1254030A1 (zh) 2015-06-26 2016-06-23 治疗自身免疫病症和同种免疫病症的方法

Country Status (12)

Country Link
US (3) US20180169240A1 (https=)
EP (1) EP3313417A4 (https=)
JP (1) JP6963509B2 (https=)
KR (1) KR20180020296A (https=)
CN (1) CN108348600A (https=)
AU (2) AU2016282782A1 (https=)
CA (1) CA2990662A1 (https=)
EA (1) EA038567B1 (https=)
HK (1) HK1254030A1 (https=)
IL (1) IL256424B2 (https=)
MX (2) MX2017016835A (https=)
WO (1) WO2016210172A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
WO2016164358A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
AU2017258492B2 (en) 2016-04-29 2023-12-07 Pfizer Inc. Interferon beta antibodies and uses thereof
HUE073475T2 (hu) 2016-10-12 2026-01-28 Bioverativ Usa Inc C1s elleni antitestek és alkalmazási eljárásaik
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHOD OF USING
MX2021013441A (es) 2019-05-15 2021-12-10 Chugai Pharmaceutical Co Ltd Molecula de union a antigenos, composicion farmaceutica y metodo.
TWI856193B (zh) * 2019-10-16 2024-09-21 日商中外製藥股份有限公司 抗體、醫藥組成物及方法
IL300376A (en) * 2020-08-06 2023-04-01 Bioverativ Usa Inc Inflammatory cytokines and fatigue in subjects with complement-mediated disease
US11958899B2 (en) 2021-07-13 2024-04-16 Mabwell Therapeutics Inc. Anti-C1s antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6929100A (en) * 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
WO2004022096A1 (en) * 2002-09-06 2004-03-18 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
WO2009132058A2 (en) * 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
NZ597259A (en) * 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
CN104870475B (zh) * 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
DK2914291T3 (da) * 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf

Also Published As

Publication number Publication date
JP6963509B2 (ja) 2021-11-10
IL256424B2 (en) 2024-09-01
AU2022215307A1 (en) 2022-09-08
CA2990662A1 (en) 2016-12-29
US20180169240A1 (en) 2018-06-21
EA038567B1 (ru) 2021-09-15
IL256424A (en) 2018-02-28
MX2017016835A (es) 2018-08-01
EA201890106A1 (ru) 2018-05-31
BR112017027578A2 (pt) 2018-08-28
IL256424B1 (en) 2024-05-01
MX2023002021A (es) 2023-03-15
US20220249664A1 (en) 2022-08-11
US20250295768A1 (en) 2025-09-25
EP3313417A1 (en) 2018-05-02
AU2016282782A1 (en) 2018-01-18
WO2016210172A1 (en) 2016-12-29
EP3313417A4 (en) 2019-06-12
JP2018526330A (ja) 2018-09-13
CN108348600A (zh) 2018-07-31
NZ738570A (en) 2025-05-02
KR20180020296A (ko) 2018-02-27
AU2022215307B2 (en) 2025-09-04

Similar Documents

Publication Publication Date Title
HK1254030A1 (zh) 治疗自身免疫病症和同种免疫病症的方法
Radley et al. Chronic stress and brain plasticity: mechanisms underlying adaptive and maladaptive changes and implications for stress-related CNS disorders
HK1222780A1 (zh) 具有微流体系统的眼科镜片
WO2016073380A8 (en) Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
AU2018260845A1 (en) Evaluation and treatment of bradykinin-mediated disorders
HK1250752A1 (zh) 治疗骨髓增生性障碍的方法
EP2959280A4 (en) METHOD FOR LANGUAGE DECODING OF THE BRAIN AND SYSTEMS FOR CARRYING OUT THEREOF
EP2957336A3 (en) Methods for increasing the capacity of flow-through processes
MX368725B (es) Sistema cerrado integrado de extraccion de linea intravenosa.
WO2015153864A3 (en) Methods for treating inflammatory conditions
MX2017015758A (es) Componente de dispositivo, dispositivo, y metodo para purificar y ensayar biomoleculas de muestras biologicas.
HK1252827A1 (zh) 结合lag-3的分子和其使用方法
WO2016063068A3 (en) Method and apparatus for the analysis of compounds
WO2016012285A3 (en) Method
WO2013142796A3 (en) Methods of treatments using ctla4 antibodies
WO2008090360A8 (en) Methods
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
EP3361263A4 (en) SAMPLE TREATMENT SCHIP, SAMPLE TREATMENT METHOD AND SAMPLE TREATMENT METHOD
CA2863417A1 (en) Innate immune proteins as biomarkers for cns injury
WO2017024019A8 (en) Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
MX2021013459A (es) Medicion rapida de la tasa de sedimentacion de los componentes sanguineos formados a partir de peque?os volumenes de muestra.
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
WO2015042326A3 (en) Methods for detection and treatment of neurodegenerative diseases
WO2015168602A3 (en) Methods and compositions for the diagnosis and treatment of kawasaki disease
MY185990A (en) Marker for acid sphingomyelinase disorders and uses thereof